UNSPSC 51182063: Oxabolone cipionate

This classification denotes an anabolic steroid with the molecular formula C26H38O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5RXY50Q01N, chemically known as 4,17beta-dihydroxyestr-4-en-3-one 17-cyclopentanepropionate but more generally known as oxabolone cipionate, which bears US NIH Compound Identifier 68952. European Medicines Agency schedules Oxabolone cipionate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09481MIG. The term OXABOLONE CIPIONATE is an International Non-Proprietary Name.

UNSPSC 51182063 Oxabolone cipionate, a Commodity code, encompasses pharmaceutical products supplied through state and local cooperative purchasing agreements that aggregate demand across multiple participating jurisdictions. State and local governments procure generic pharmaceuticals and over-the-counter products under this code through multistate cooperative purchasing vehicles, with wholesalers serving as the distribution intermediaries to state agencies, local health departments, corrections facilities, and other public health entities. The actual work involves manufacturers submitting detailed product specifications, pricing schedules, and compliance documentation — including National Drug Codes, packaging configurations, manufacturing locations, and proof of Good Manufacturing Practices (cGMP) and Drug Supply Chain Security Act (DSCSA) certification — to qualify for award on statewide or multistate contracts with terms typically spanning two years and subject to optional extensions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, posted a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products across participating states including Oregon. Evaluation is weighted heavily toward price competitiveness (75 percent), with secondary criteria including fixed pricing structure (10 percent), price format compliance (5 percent), EDI capability (5 percent), and willingness to accept a 3 percent administrative fee (5 percent). Vendors must maintain relationships with at least two of three authorized wholesalers — AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC — and carry comprehensive insurance including $5 million commercial general liability and $2 million network security and privacy liability. Awards become effective July 1, 2026, with awarded vendors subject to performance penalties of $200 to $1,500 per violation for late reporting, missed onboarding deadlines, or improper class-of-trade denials.